132
Participants
Start Date
July 1, 2023
Primary Completion Date
October 31, 2024
Study Completion Date
December 31, 2025
Trilaciclib
IV infusion, d1
Carboplatin
IV infusion, d1
Paclitaxel
IV infusion, d1
Tislelizumab
IV infusion, d1
Chengdu First People's Hospital
OTHER
Chengdu Second people's hospital
UNKNOWN
Chengdu Seventh People's Hospital
UNKNOWN
Mianyang Central Hospital
OTHER
Shaanxi Provincial Cancer Hospital
OTHER
Shandong Cancer Hospital and Institute
OTHER
Heilongjiang Provincial Cancer Hospital
UNKNOWN
Enshi Central Hospital
UNKNOWN
Neijiang Hospital of Traditional Chinese Medicine
UNKNOWN
Sichuan University
OTHER